Le Lézard
Classified in: Sports and recreation, Covid-19 virus
Subject: NEW PRODUCTS/SERVICES

Ayurcann Holdings Corp. Expands Across Canada With Sales Into Manitoba for Branded Vapes and Tinctures


PICKERING, Ontario, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR) (FSE:3ZQ0) (the "Company" or "Ayurcann") a Canadian cannabis extraction company specializing in the processing and manufacturing of cannabis to produce cannabis 2.0 and 3.0 products into the Canadian market, is pleased to announce that their Fuego and Vida brands are available for sale in Manitoba.

Ayurcann is growing its presence across Canada by manufacturing and creating appealing and value-based products for the recreational market. Consumers across the country are demanding products that provide quality, a unique experience, and value when it comes to their cannabis consumption. Ayurcann is excelling in fulfilling those needs.

Ayurcann has continuously grown its SKU count and uses its R&D license to create new offerings to be submitted to Health Canada in the Vape, Tincture, and Topical categories.

Ayurcann is now available in 4 provinces and is creating a unique opportunity for national and international brands to enhance their offerings to the Canadian consumer through brand representation and partnerships.

The available products include the Fuego branded vapes; Fuego Pink Kush, Fuego Cherry Blossom OG, Fuego Citrus and the Fuego Wedding Crasher as well as the Vida Tincture line, the CBD 50, and the CBD 1:1.

"We are excited that consumers in Manitoba will be able to enjoy our premium quality products," stated Igal Sudman, CEO of Ayurcann. "There is a market demand for value-priced, high-quality cannabis-derived products, and we are confident that the various products and brands we bring to market will meet this consumer need."

For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322
Email: [email protected]

Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: [email protected]

About Ayurcann Holdings Corp.:

Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company's expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company's facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company's business, financial condition and/or results of operations.  The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.



These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:05
Teck Resources Limited (Teck) today announced its unaudited first quarter results for 2024. "All outstanding major construction at our QB operation was completed in the first quarter, including the shiploader and molybdenum plant, and we marked the...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...

24 avr 2024
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024. Highlights for the Quarter: Net income available to common...



News published on and distributed by: